Loading company
Just reported
From AtriCure's results release of November 3, 2026; its quarterly report has since been filed.
Actual
$154.5M
+15% y/y
+0.6% q/q
Guided
—
No guide given
Actual
$0.08
-56% q/q
Guided
—
No guide given
Actual
$4.4M
-55% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes AtriCure is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.$155.8BA+
MDLNMedline Inc.$55.5BA
ALCAlcon Inc.$35.3BA
BLCOBausch & Lomb Corp$7.6BA-
RMDResMed Inc.$33.5BB+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now ABuilt from AtriCure, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Company outlook: revenue of $606M to $610M for Fiscal year 2026 — up 13.7% on a year earlier
Grade A
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of AtriCure, Inc.’s grade history. The other 39 go back to October 2016.
